Media Center

Publicacions

Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models

Published online: 02 Nov 2022
https://doi.org/10.3389/fonc.2022.943064

Andrea Mancini, Alessandro Colapietro, Loredana Cristiano, Alessandra Rossetti, Vincenzo Mattei, Giovanni Luca Gravina, Héctor Perez-Montoyo, Marc Yeste-Velasco, Jose Alfon, Carles Domenech, Claudio Festuccia

ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models

Posted online: 1 June 2022
https://doi.org/10.1002/cac2.12282

Emma Polonio‐Alcalá, Sònia Solé‐Sánchez, Pau Muñoz‐Guardiola, Elisabet Megías‐Roda, Héctor Perez‐Montoyo, Marc Yeste‐Velasco, Jose Alfón, Jose Miguel Lizcano, Carles Domènech, Santiago Ruiz‐Martínez and Teresa Puig

Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC

IASLC, 2020 World Conference on Lung Cancer, Singapore, January 2021

J. Bosch-Barrera, et al.

Phase 2 of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin as first-line treatment in advanced/recurrent endometrial cancer

ESMO 2020 - Abstract 2727

A. Leary , P. Estévez-García, R. Sabatier, L. Fariñas-Madrid, J.A. Perez-Fidalgo, M. Romeo, M.P. Barretina-Ginesta, M. Gil-Martin, E. Garralda , J. Rodon, J.M. Lizcano, P. Muñoz-Guardiola , H. Pérez-Montoyo , M. Yeste-Velasco , M. Cortal ,
C. Domènech , J. Alfon, I. Ray-Coquard, A. Oaknin

The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.

Posted online: 13 May 2020
https://doi.org/10.1080/15548627.2020.1761651

Pau Muñoz-Guardiola,Josefina Casas,Elisabet Megías-Roda,Sònia Solé,Héctor Perez-Montoyo,Marc Yeste-Velasco,Tatiana Erazo,Nora Diéguez-Martínez,Sergio Espinosa-Gil,Cristina Muñoz-Pinedo,Guillermo Yoldi,Jose L Abad,Miguel F Segura,Teresa Moran,Margarita Romeo,Joaquim Bosch-Barrera,Ana Oaknin,Jose Alfón,Carles Domènech,Gemma Fabriàs,Guillermo Velasco & Jose M Lizcano

Phase 1 of ABTL0812, a proautophagic drug, in combination with paclitaxel and carboplatin at first-line in advanced endometrial cancer and squamous cell lung carcinoma

Meeting: 2019 ASCO Annual Meeting - Abstract No: 3089 - Poster Board Number: Poster Session (Board 81) - Citation: J Clin Oncol 37, 2019 (suppl; abstr 3089)

Author(s): Lorena Farinas-Madrid, Purificación Estévez-García, Jose Alejandro Perez-Fidalgo, Joaquim Bosch-Barrera, Teresa Moran, Ernest Nadal, Victor Rodriguez Freixinos, Elisa Calvo, Alejandro Falcon, Paloma Martín-Martorell, Marisol Huerta Alvaro, Maria Pilar Barretina-Ginesta, Margarita Romeo, Marta Gil-Martin, Elena Garralda, Jordi Rodon, Jose M. Lizcano, Carles Domenech, Jose Alberto Alfon, Ana Oaknin; Vall d’Hebron University Hospital Institute of Oncology (VHIO), Barcelona, Spain; Unidad de Tumores Ginecológicos y Genitourinarios, Servicio de Oncologia Médica, Hospital Universitario Virgen del Rocío, Seville, Spain; INCLIVA Research Institute and Hospital Clínico Universitario de Valencia, Valencia, Spain; Institut Catala d'Oncologia, Universitary Hospital Dr. Josep Trueta, Girona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain; Institut Català d’Oncologia, L’Hospitalet, Barcelona, Spain; Vall d'Hebron Institut of Oncology, Barcelona, Spain; Servicio de Oncologia Médica, Hospital Universitario Virgen del Rocío, Seville, Spain; Medical Oncology Department. Hospital Universitario Virgen del Rocío, Seville, Spain; Hospital Clinic Universitario de Valencia, Valencia, Spain; Oncología Médica, Hospital Universitario de Valencia, Valencia, Spain; Medical Oncology Department, Catalan Institute of Oncology, Girona, Spain; Medical Oncology Department, Institut Català d’Oncologia (ICO) Badalona, B-ARGO, Badalona, Spain; Institut Català d'Oncologia-ICO L’Hospitalet, Barcelona, Spain; Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; Institut de Neurociencies, Universitat Autonoma de Barcelona, Bellaterra, Barcelona, Spain; Ability Pharmaceuticals, Barcelona, Spain; Ability Pharmaceuticals SL, Cerdanyola Del Valles, Spain; Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.

Published: Gynecol Oncol. 2019 Mar 7

S0090-8258(19)30150-7

Felip I, Moiola CP, Megino-Luque C, Lopez-Gil C, Cabrera S, Solé-Sánchez S, Muñoz-Guardiola P, Megias-Roda E, Pérez-Montoyo H, Alfon J, Yeste-Velasco M, Santacana M, Dolcet X, Reques A, Oaknin A, Rodríguez-Freixinos V, Lizcano JM, Domènech C, Gil-Moreno A, Matias-Guiu X, Colas E, Eritja N.

ABTL0812, a novel phase-2 clinical stage pro-autophagic anti-cancer compound with potential clinical activity in cholangiocarcinoma

2019 Cholangiocarcinoma Foundation Annual Conference

Hector Perez-Montoyo, Paula Olaizola, Pau Muñoz-Guardiola, Elisabet Megias-Roda, Sonia Sole, Marta Gil, Laura Vidal, Pere Gascon, Jose M. Lizcano, Carles Domenech, Jesus M. Banales and Jose Alfon

Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.

1st Oncobell Symposium. Mechanisms of Cancer and New Therapeutic Strategies. Barcelona 2018.

P. Muñoz-Guardiola, E. Megías-Roda, T. Erazo, H. Pérez, S. Solé-Sánchez, N. Diéguez, M. Yeste, M. Cortal, G. Velasco, J. Alfon, C. Domènech, J.M. Lizcano.

Exploring pharmacokinetic/pharmacodynamic considerations in translational oncology; from preclinical development to Phase II operations

Outsourcing in Clinical Trials. Barcelona 2018.

Jose Alfón

Preclinical and clinical development of ABTL0812: a new antitumoral drug that induces autophagy-mediated cancer cell death by upregulating TRIB3 pseudokinase and impairing of Akt/mTORC1 axis.

16th International Congress ASEICA, 2018.

P. Muñoz-Guardiola, T. Erazo, E. Megías-Roda, H. Pérez-Montoyo, S. Solé-Sánchez, N. Diéguez-Martínez, M. Yeste, M. Cortal, L. Vidal, P. Gascon, M. Gil, M. Romeo, T. Moran, G. Velasco, Jose Alfón, C. Domènech, J.M. Lizcano.

Development of TRIB3 as a novel preclinical and clinical pharmacodynamic biomarker for ABTL0812

J Clin Oncol 36, 2018 (suppl; abstr e14556).

H. Pérez-Montoyo, M. Yeste-Velasco, S. Solé-Sánchez, P. Bragado, E. Colàs-Ortega, N. Eritja, A. Lopez-Plana, P. Fernandez-Nogueira, P. Muñoz-Guardiola, E. Megías-Roda, C. Moiola, I. Felip, E. Nadal-Alforja, M. Gil Martin, M. Romeo, T. Moran, A. Gil-Moreno, X. Matias-Guiu, C. Domenech, J.M. Lizcano

The new antitumoral drug ABTL0812 induces autophagic cell death by a dual mechanism: inhibition of Akt/mTORC1 axis and impairing desaturase-1 activity.

Transautophagy, Copenhaguen 2017.

Pau Muñoz-Guardiola, Josefina Casas , Elisabet Megías, Nora Diéguez, Mar Lorente, Pedro Rayo, Tatiana Erazo, Sònia Solé-Sánchez, José Alfón, Carles Domènech, Héctor Pérez, Guillermo Velasco, Gemma Fabriàs, Jose M. Lizcano.

Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling

Published: 11 Oct. 2016

Ann Oncol (2016) 27 (suppl_6): 378P

J. Alfon L. Vidal L. Gaba I. Victoria M. Gil B. Laquente M. Brunet H. Colom J. Ramis H. Perez-Montoyo M. Cortal M. Gomez-Ferreria P. Muñoz T. Erazo J.M. Lizcano C. Domenech P. Gascon

The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase

Published: 15 May 2016

10.1158/1078-0432.CCR-15-1808

Tatiana Erazo, Mar Lorente, Anna López-Plana, Pau Muñoz-Guardiola, Patricia Fernández-Nogueira, José A. García-Martínez, Paloma Bragado, Gemma Fuster, María Salazar, Jordi Espadaler, Javier Hernández-Losa, Jose Ramon Bayascas, Marc Cortal, Laura Vidal, Pedro Gascón, Mariana Gómez-Ferreria, José Alfón, Guillermo Velasco, Carles Domènech and Jose M. Lizcano

ÚLTIMES NOTÍCIES

11.03.2024

Notes de Premsa

AbilityPharma tanca una ronda d'inversió de 7 milions d'euros per al fàrmac ABTL0812 en fase clínica 2b en càncer de pàncrees metastàtic + info
02.06.2023

Notes de Premsa

Ability Pharmaceuticals anuncia la presentació dels resultats de la fase 2a d’ABTL0812 com a teràpia de primera línia en pacients amb càncer de pulmó al congrés anual ASCO 2023 a Chicago + info
14.12.2022

Notes de Premsa

AbilityPharma aconsegueix el 30% de la contractació estimada per al seu assaig clínic de fase 2b amb ABTL0812 + FOLFIRINOX com a tractament terapèutic de primera línia en càncer de pàncrees avançat + info
21.11.2022

Notes de Premsa

AbilityPharma obté 1,5 milions d'euros de finançament no dilutiu de la propera generació de fons de la UE per aprofundir en l'estudi dels efectes immunomoduladors contra el càncer d'ABTL0812 + info
10.11.2022

Notes de Premsa

AbilityPharma participarà al LSX Investival Showcase a Londres per reunir-se amb potencials inversors i firmes de capital risc + info
02.11.2022

Notes de Premsa

ABTL0812 mostra potencial contra els tumors cerebrals de glioblastoma + info
07.10.2022

Notes de Premsa

AbilityPharma aconsegueix 2,2M € de finançament no dilutiu del Ministeri de Ciència i Innovació del Govern d'Espanya per accelerar el desenvolupament clínic i la ruta reguladora de ABTL0812 + info
07.09.2022

Notes de Premsa

Carles Domènech, president executiu i director general d'AbilityPharma, assistirà al congrés ESMO a París per reunir-se amb alguns dels líders d'opinió clau (KOL) més rellevants en el tractament del càncer de pàncrees + info
29.06.2022

Notes de Premsa

AbilityPharma participarà al congrés mundial de l'ESMO en càncer gastrointestinal 2022 a Barcelona + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG